Abstract

You have accessJournal of UrologyKidney Cancer: Evaluation & Staging (I)1 Apr 2013623 IDENTIFICATION OF HIGH RISK PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA BASED ON INTERPHASE-FISH Jimsgene Sanjmyatav, Sophie Matthes, Martin Mühr, Doriana Sava, Maria Sternal, Mieczeslaw Gajda, Heiko Wunderlich, Marc-Oliver Grimm, and Kerstin Junker Jimsgene SanjmyatavJimsgene Sanjmyatav Jena, Germany More articles by this author , Sophie MatthesSophie Matthes Jena, Germany More articles by this author , Martin MührMartin Mühr Jena, Germany More articles by this author , Doriana SavaDoriana Sava Jena, Germany More articles by this author , Maria SternalMaria Sternal Jena, Germany More articles by this author , Mieczeslaw GajdaMieczeslaw Gajda Jena, Germany More articles by this author , Heiko WunderlichHeiko Wunderlich Eisenach, Germany More articles by this author , Marc-Oliver GrimmMarc-Oliver Grimm Jena, Germany More articles by this author , and Kerstin JunkerKerstin Junker Homburg, Germany More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.175AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES By precise genetic mapping of clear cell renal cell carcinomas using array-CGH we identified in our previous studies specific chromosomal aberrations which were significantly associated both with metastasis and cancer specific survival. The aim of this study was to examine the prognostic value of the 4 most significant aberrations in an extended cohort of patients in order to develop a prognostic FISH assay in the future. METHODS FISH experiments were performed on isolated cell nuclei from 100 ccRCCs (52 metastasized/48 non-metastasized). The mean/median follow-up of patients was 59/54 months. For each critical chromosomal region (1q21.3, 7q36.3, 9p21.3p24.1 und 20q11.21q13.32) we used commercially available FISH probes. The data from FISH-experiments was dichotomized by using ROC-curve analysis and the total number of specific aberrations (TNSA) was calculated for each tumor based on the specific genomic alterations. RESULTS TNSA was the best predictor of metastasis (AUC=0.814) compared to single aberrations (AUC: 0.619-0.708) and to 11 different combinations of these 4 aberrations in the ROC-curve analysis. TNSA, tumor grade and tumor size were independent predictors of metastasis in the multivariate analysis (p<0.001) for the whole cohort as well as organ confined tumors. TNSA and Fuhrman grade could also independently predict cancer-specific mortality (CSM). Furthermore, in our cohort TNSA demonstrated the highest significance in COX proportional hazard models of overall survival (OS), cancer-specific survival (CSS) and progression-free survival (PFS). CONCLUSIONS We identified TNSA as an independent prognostic factor which is associated with metastasis occurrence, CSM, OS, CSS and PFS in patients with ccRCCs. These data clearly show that an individual prognosis assessment is possible based on genomic changes in the primary tumor of patients with ccRCC. © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e254-e255 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.MetricsAuthor Information Jimsgene Sanjmyatav Jena, Germany More articles by this author Sophie Matthes Jena, Germany More articles by this author Martin Mühr Jena, Germany More articles by this author Doriana Sava Jena, Germany More articles by this author Maria Sternal Jena, Germany More articles by this author Mieczeslaw Gajda Jena, Germany More articles by this author Heiko Wunderlich Eisenach, Germany More articles by this author Marc-Oliver Grimm Jena, Germany More articles by this author Kerstin Junker Homburg, Germany More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.